Drug intelligence / Profile preview

MOS103

Development stage: Preclinical
Lead developer: Mosaic Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

MOS103 is a small molecule MDM2 inhibitor being developed by Mosaic Therapeutics for the treatment of p53 wild-type (WT) myelofibrosis. As an MDM2-targeting agent, MOS103 acts by disrupting the interaction between the MDM2 E3 ubiquitin ligase and the p53 tumor suppressor protein. This inhibition prevents the proteasomal degradation of p53, thereby restoring its activity and promoting cell cycle arrest and apoptosis in malignant cells that retain wild-type p53. The program is currently in the IND-enabling phase and is being positioned for first-line use, potentially in combination with other therapeutic agents.

Targets

MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on MOS103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOS103.

Explore the full profile